Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy

Abstract

Antibody conjugated nanoparticles (ACNPs) represent a novel strategy for the development of therapies exploiting antibodies to augment the delivery of chemotherapy payloads. Following in the footsteps of the success of antibody drug conjugates (ADCs), ACNPs are only now reaching clinical evaluation. In this review we discuss the success of ADCs and explore the opportunities ACNPs offer, such as broad chemotherapy payload selection, high drug to antibody ratios and the ability to finely tailor drug release in comparison to ADCs. The ability of ACNPs to elicit increased avidity due to multivalent effects and the potential to use these modular platforms in immunotherapeutic approaches is also explored. Through addressing challenges that still remain in bringing these complex formulations to the clinic, ACNPs hold obvious potential for the treatment of a wide range of cancers and other diseases where selective targeting of drug agents is essential.

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

“…This article was the proof of concept for the incorporation of PROTACs into nanoparticles. A further next step is the development of ACNPs as a combination of the potential of antibody conjugation and nanotechnology [ 26 , 27 ]. Antibodies against membrane proteins expressed in tumoral cells can be used as vectors.…”

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer

“…The possibility to carry targeted therapies in nanocarriers through a conjugation with antibodies is being proposed as a novel strategy in oncology [19,20]. The antibody-drug conjugated nanoparticles (ACNPs) could deliver the drug in a controlled manner, reducing toxicity [21]. The identification of membrane proteins overexpressed in tumoral cells is needed when designing the use of antibodies to be used as the NP vector.…”

Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells

“…Crucially, these factors may be overcome by our antibody-targeted nanoparticles described herein, which allow for higher drug loading on a per vehicle basis and do not necessitate linker technology since the payload is entrapped within the polymeric core. 45,46…”